The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Adverse outcomes (AOs) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) treated with intensified androgen deprivation therapy (ADT+).
 
Nabiel Ali Mir
Research Funding - Conquer Cancer, the ASCO Foundation (Inst); Richard and Debra Gonzalez Research Fellowship (Inst)
 
Waqaas Akmal
No Relationships to Disclose
 
Maaz Imam
No Relationships to Disclose
 
Mihai Giurcanu
Research Funding - NIH
 
Russell Zelig Szmulewitz
Honoraria - Astellas Pharma; Pfizer/Astellas
Consulting or Advisory Role - Abbvie; Amgen; Astellas Pharma; AstraZeneca; Eisai; Exelixis; Janssen Oncology; Merck; Novartis; Pfizer; Sanofi
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); Harpoon therapeutics (Inst); Janssen Oncology (Inst); Macrogenics (Inst); Merck (Inst); Novartis (Inst); Plexxikon (Inst); Progenics (Inst)
Patents, Royalties, Other Intellectual Property - Patent licensed by University of Chicago of which I am co-inventor to Corcept Therapeutics for combination AR/GR inhibition in prostate cancer
Travel, Accommodations, Expenses - Corcept Therapeutics
 
Walter Michael Stadler
Leadership - EMA Wellness
Stock and Other Ownership Interests - Fortress Biotech
Consulting or Advisory Role - AstraZeneca; Bayer; Calico; CVS Caremark; Merck; Pfizer; Treadwell Therapeutics
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Medivation (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Corvus Pharmaceuticals (Inst); Eisai (Inst); Exelixis (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Johnson & Johnson (Inst); Merck (Inst); Millennium (Inst); Novartis (Inst); Pfizer (Inst); Seagen (I); Tesaro (Inst); X4 Pharma (Inst); Xencor (Inst)
Expert Testimony - Apotex; Sandoz
Other Relationship - American Cancer Society; UpToDate